MARKET

CHRS

CHRS

Coherus
NASDAQ
0.8800
+0.0128
+1.48%
After Hours: 0.8982 +0.0182 +2.07% 18:06 07/11 EDT
OPEN
0.8700
PREV CLOSE
0.8672
HIGH
0.9118
LOW
0.8500
VOLUME
1.68M
TURNOVER
--
52 WEEK HIGH
2.430
52 WEEK LOW
0.6603
MARKET CAP
102.02M
P/E (TTM)
-0.7765
1D
5D
1M
3M
1Y
5Y
1D
Alvotech: A Fast-Expanding Biosimilar Concern
Seeking Alpha · 5h ago
Top rated and bottom rated stocks according to 3 key drivers of performance – UBS
Seeking Alpha · 6h ago
Truist Financial Reaffirms Their Buy Rating on Coherus Biosciences (CHRS)
TipRanks · 2d ago
Weekly Report: what happened at CHRS last week (0630-0704)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 07/03 21:05
Coherus Biosciences Receives Nasdaq Deficiency Notice
TipRanks · 07/03 20:30
Weekly Report: what happened at CHRS last week (0623-0627)?
Weekly Report · 06/30 09:59
Weekly Report: what happened at CHRS last week (0616-0620)?
Weekly Report · 06/23 09:56
More
About CHRS
Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).

Webull offers Coherus Oncology Inc stock information, including NASDAQ: CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CHRS stock methods without spending real money on the virtual paper trading platform.